We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Targeted testing of bone marrow specimens with cytoplasmic vacuolization to identify previously undiagnosed cases of VEXAS syndrome.
- Authors
Hines, Alexander S; Koster, Matthew J; Bock, Allison R; Go, Ronald S; Warrington, Kenneth J; Olteanu, Horatiu; Lasho, Terra L; Patnaik, Mrinal M; Reichard, Kaaren K
- Abstract
Objective To retrospectively identify patients with VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome) among male patients with bone marrow vacuolization using a clinically applicable, targeted-screening approach. Methods Bone marrow reports from 1 May 2014 through 18 February 2022 were reviewed for documentation of cytoplasmic vacuolization. Patients with acute leukaemia, lymphoma, metastatic solid tumour, amyloidosis or POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome were excluded, as were those without clinical records available for direct chart review. Cases were rated for suspicion of VEXAS syndrome using a 5-point scale based on the presence of laboratory findings, clinical features and treatment response. Patients with available DNA material and moderate (three patients) or high (four to five patients) suspicion were tested for somatic UBA1 variants associated with VEXAS syndrome. Results A total of 315 reports from 292 unique patients included documentation of vacuolization. Following exclusion criteria, 64 patients underwent direct medical chart review to assess likelihood of VEXAS syndrome, for which 21 patients met moderate to high suspicion. Available DNA was present in eight patients, seven (87.5%) of whom had a pathogenic somatic UBA1 variant consistent with VEXAS syndrome. The distribution of cytoplasmic vacuolization in the bone marrow biopsy reports among patients with VEXAS syndrome were erythroid and myeloid precursors (6/7), erythroid precursors only (1/7) and myeloid precursors only (0/7). Conclusion In this study, the utilization of a clinically applicable targeted-screening approach to test bone marrow specimens (with vacuolization) for the presence of previously undiagnosed VEXAS syndrome resulted in a positive detection rate of 87.5%.
- Subjects
DNA; MEDICAL screening; RETROSPECTIVE studies; ACQUISITION of data; DOCUMENTATION; MEDICAL records; DESCRIPTIVE statistics; COLLECTION &; preservation of biological specimens; AUTOINFLAMMATORY diseases; BONE marrow examination; CYTOPLASM
- Publication
Rheumatology, 2023, Vol 62, Issue 12, p3947
- ISSN
1462-0324
- Publication type
Article
- DOI
10.1093/rheumatology/kead245